SYMBIO PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 172 JPY | -1.15% |
|
-3.37% | -30.36% |
Valuation
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Capitalization 1 | 25,399 | 10,421 |
| Enterprise Value (EV) 1 | 19,117 | 3,904 |
| P/E ratio | 21.6 x | -5.02 x |
| Yield | - | - |
| Capitalization / Revenue | 2.54 x | 1.86 x |
| EV / Revenue | 1.91 x | 0.7 x |
| EV / EBITDA | 9.27 x | -5.47 x |
| EV / FCF | 12.4 x | -27.2 x |
| FCF Yield | 8.07% | -3.68% |
| Price to Book | 2.99 x | 1.45 x |
| Nbr of stocks (in thousands) | 39,501 | 42,191 |
| Reference price 2 | 643.0 | 247.0 |
| Announcement Date | 3/23/23 | 3/22/24 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Net sales 1 | 10,008 | 5,589 |
| EBITDA 1 | 2,063 | -714 |
| EBIT 1 | 1,964 | -812 |
| Operating Margin | 19.62% | -14.53% |
| Earnings before Tax (EBT) 1 | 2,106 | -1,195 |
| Net income 1 | 1,179 | -1,962 |
| Net margin | 11.78% | -35.1% |
| EPS 2 | 29.77 | -49.17 |
| Free Cash Flow 1 | 1,542 | -143.5 |
| FCF margin | 15.41% | -2.57% |
| FCF Conversion (EBITDA) | 74.75% | - |
| FCF Conversion (Net income) | 130.8% | - |
| Dividend per Share | - | - |
| Announcement Date | 3/23/23 | 3/22/24 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2021 S1 | 2021 Q3 |
|---|---|---|---|
| Net sales 1 | 1,360 | 3,146 | 2,407 |
| EBITDA | - | - | - |
| EBIT 1 | -1,839 | -194 | 618 |
| Operating Margin | -135.22% | -6.17% | 25.68% |
| Earnings before Tax (EBT) 1 | -1,883 | -203 | 617 |
| Net income 1 | -1,884 | -205 | 529 |
| Net margin | -138.53% | -6.52% | 21.98% |
| EPS 2 | -62.47 | -5.370 | 13.85 |
| Dividend per Share | - | - | - |
| Announcement Date | 8/5/20 | 8/4/21 | 11/11/21 |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Net Debt 1 | - | - |
| Net Cash position 1 | 6,282 | 6,517 |
| Leverage (Debt/EBITDA) | - | - |
| Free Cash Flow 1 | 1,542 | -144 |
| ROE (net income / shareholders' equity) | 15.5% | -25% |
| ROA (Net income/ Total Assets) | 13% | -5.46% |
| Assets 1 | 9,070 | 35,960 |
| Book Value Per Share 2 | 215.0 | 171.0 |
| Cash Flow per Share 2 | 159.0 | 154.0 |
| Capex 1 | 2 | 204 |
| Capex / Sales | 0.02% | 3.65% |
| Announcement Date | 3/23/23 | 3/22/24 |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -30.36% | 51.22M | |
| +26.83% | 681B | |
| +21.85% | 556B | |
| -4.91% | 361B | |
| +17.24% | 325B | |
| +5.90% | 285B | |
| +13.68% | 235B | |
| +3.65% | 199B | |
| -11.12% | 189B | |
| -3.94% | 157B |
- Stock Market
- Equities
- 4582 Stock
- Financials SymBio Pharmaceuticals Limited
